相关实验视频
Updated: Jun 3, 2025

13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
17.5K
将痴呆症研究转化为实践:在荷兰阿尔茨海默症中心对学术研究利用策略的多个案例研究
Eden Meng Zhu1, Martina Buljac-Samardžić2, Kees Ahaus2
1Erasmus School of Health Policy & Management, PO Box 1738, 3000 DR, Rotterdam, Netherlands. zhu@eshpm.eur.nl.
Health research policy and systems
|January 6, 2025
概括
学术痴呆症中心使用各种策略来实施非药物干预. 成功利用研究需要调整研究人员的技能,并与最终用户共同创造更好的痴呆症护理.
科学领域:
- 实施科学 实施科学
- 痴呆症研究 痴呆症研究
- 医疗保健服务研究 医疗服务研究
背景情况:
- 传统的大学设置在将非药物痴呆症研究转化为实践方面面临挑战.
- 荷兰建立了五个阿尔茨海默症中心,以协调和促进痴呆症研究知识利用.
- 本研究探讨了这些中心的研究利用策略,使用知识转化为行动 (KTA) 框架.
研究的目的:
- 系统地探索荷兰阿尔茨海默症中心的学术研究人员使用的研究利用策略.
- 了解知识转化为行动 (KTA) 框架如何适用于痴呆症研究实施.
- 确定影响非药物痴呆症研究转化为实践的因素.
主要方法:
- 在五个荷兰阿尔茨海默症中心对29名受访者进行了个别的半结构性定性访谈.
- 使用有目的的 (雪球) 采样来选择参与者.
- 根据知识转化为行动 (KTA) 框架的维度指导,分析了采访数据.
主要成果:
- 在五个阿尔茨海默症中心观察到研究利用策略的显著差异.
- 战略受到研究产品类型和中心组织背景的影响.
- 资助者和患者/组织的共同创造促进了知识的创造和适应;传播和实施利用了技术转让办公室和伙伴关系.
结论:
- 有效的研究利用需要不断发展的研究人员能力和与最终用户和合作伙伴的共同创造.
- 了解外部决定因素对于能力建设和协调荷兰痴呆症研究生态系统的议程至关重要.
- KTA框架有效地阐明了研究利用的复杂性,在各种背景下为未来的研究提供了信息.
相关概念视频
Archival Research
15.9K
Some researchers gain access to large amounts of data without interacting with a single research participant. Instead, they use existing records to answer various research questions. This type of research approach is known as archival research. Archival research relies on looking at past records or data sets to look for interesting patterns or relationships. For example, a researcher might access the academic records of all individuals who enrolled in college within the past ten years and...
15.9K
Documentation in Long-Term and Home Healthcare Setting
873
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
873
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161

